Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also dissolves in common polar solvents |
| Storage temperature | Minus 20 degrees Celsius or lower | Applies to dry powder, desiccated and dark |
| Typical analytical methods | Reversed-phase HPLC and mass spectrometry | Used together for purity and identity |
| Primary degradation route | Hydrolysis and aggregation | No cysteine present, so disulfide formation is unlikely |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
=== The Banana gang === In 2015, the Belgian authorities dismantled the Belgian-Moroccan Banana gang (Dutch: De Bananenbende), which was led by Karim A., Nabil A. and Khalid O.H., after a seizure that contained 3.4 tonnes of cocaine in Antwerp. The drugs were hidden in two containers of bananas from Colombia that had passed through Ecuador. The drugs were estimated of being worth near €100 million. The investigators admitted that the clan had been importing shipments of this type for many years and that they had important links with several Moroccan clans in the Netherlands. Fourteen people were arrested, including the manager of a hookah bar in Antwerp, and the owner of a car dealership. The Belgian intelligence services estimated that this clan generated around €300 million a year, with importing no more than 10 tonnes of cocaine from South America.
== Motivation for development == Protein microarrays were developed due to the limitations of using DNA microarrays for determining gene expression levels in proteomics. The quantity of mRNA in the cell often doesn't reflect the expression levels of the proteins they correspond to. Since it is usually the protein, rather than the mRNA, that has the functional role in cell response, a novel approach was needed. Additionally post-translational modifications, which are often critical for determining protein function, are not visible on DNA microarrays. Protein microarrays replace traditional proteomics techniques such as 2D gel electrophoresis or chromatography, which were time-consuming, labor-intensive and ill-suited for the analysis of low abundant proteins.
=== Effects during pregnancy === During human pregnancy, increased fetal production of cortisol between weeks 30 and 32 initiates production of fetal lung pulmonary surfactant to promote maturation of the lungs. In fetal lambs, glucocorticoids (principally cortisol) increase after about day 130, with lung surfactant increasing greatly, in response, by about day 135, and although lamb fetal cortisol is mostly of maternal origin during the first 122 days, 88% or more is of fetal origin by day 136 of gestation. Although the timing of fetal cortisol concentration elevation in sheep may vary somewhat, it averages about 11.8 days before the onset of labor. In several livestock species (e.g. cattle, sheep, goats, and pigs), the surge of fetal cortisol late in gestation triggers the onset of parturition by removing the progesterone block of cervical dilation and myometrial contraction. The mechanisms yielding this effect on progesterone differ among species. In the sheep, where progesterone sufficient for maintaining pregnancy is produced by the placenta after about day 70 of gestation, the prepartum fetal cortisol surge induces placental enzymatic conversion of progesterone to estrogen. (The elevated level of estrogen stimulates prostaglandin secretion and oxytocin receptor development.) Exposure of fetuses to cortisol during gestation can have a variety of developmental outcomes, including alterations in prenatal and postnatal growth patterns.
== Treatment == The mainstay of treatment for GPS is plasmapheresis, a procedure in which the affected person's blood is sent through a centrifuge and the various components are separated based on weight. The plasma contains the anti-GBM antibodies that attack the affected person's lungs and kidneys, and is filtered out. The other parts of the blood (the red blood cells, white blood cells, and platelets) are recycled and intravenously reinfused. Most individuals affected by the disease also need to be treated with immunosuppressant drugs, especially cyclophosphamide, prednisone, and rituximab, to prevent the formation of new anti-GBM antibodies to prevent further damage to the kidneys and lungs. Other, less toxic immunosuppressants such as azathioprine may be used to maintain remission.
=== Nucleic acids === The convention for a nucleic acid sequence is to list the nucleotides as they occur from the 5' end to the 3' end of the polymer chain, where 5' and 3' refer to the numbering of carbons around the ribose ring which participate in forming the phosphate diester linkages of the chain. Such a sequence is called the primary structure of the biopolymer.
Sources: en.wikipedia.org
== Function == The basic function, as already mentioned (see: Translocase § Definition), is to "catalyse the movement of ions or molecules across membranes or their separation within membranes". This form of membrane transport is classified under active membrane transport, an energy-requiring process of pumping molecules and ions across membranes against a concentration gradient. Translocases biological importance relies primarily on their critical function, in the way that they provide movement across the cell's membrane in many cellular processes that are substantial, such as:
== Interactions == The concomitant application of GM-CSFs such as filgrastim or Sargramostim showed no potential interactions. Additionally, no other interactions are known. Interactions with drugs undergoing P450 enzyme metabolism are not likely to occur.
=== Appeals === Since the amendment of the Criminal Procedure Code in 1992, all capital cases have been heard by a single judge in the High Court instead of two judges. After conviction and sentencing, the offender has the option of making an appeal to the Court of Appeal. If the appeal fails, the final recourse rests with the President of Singapore, who has the power to grant clemency on the advice of the Cabinet. In exceptional cases since 2012, the Court of Appeal would be asked to review its previous decisions in concluded criminal appeals where it was necessary to correct a miscarriage of justice, most of which involved drug cases attracting the death penalty. The exact number of successful appeals is unknown. In November 1995, one Poh Kay Keong had his conviction overturned after the court found that his statement to a Central Narcotics Bureau officer had been made under duress. Another was the case of Nadasan Chandra Secharan, who was initially found guilty of murder and condemned to death by the High Court in June 1996, but later acquitted of murder by the Court of Appeal in January 1997 after they found the evidence against him was insufficient to show that he had murdered his lover Ramapiram Kannickaisparry.
== Demography == A population's income level determines whether sufficient physicians can practice in an area and whether public subsidy is needed to maintain the health of the population. Developing countries and poor areas usually have shortages of physicians and specialties, and those in practice usually locate in larger cities. For some underlying theory regarding physician location, see central place theory. The proportion of men and women in different medical specialties varies greatly. Such sex segregation is largely due to differential application.
Sources: en.wikipedia.org
The study showed that MMP-3 accomplishes this damage by degrading claudin-5, occludin, and ZO-1 (another tight junction protein), similar to how MMP-3 damages the BBB. The increase in blood-brain barrier and blood-spinal cord barrier permeability allows for more neutrophils to infiltrate the brain and spinal cord at the site of inflammation. Neutrophils carry MMP-9., which has also been shown to degrade occludin. This leads to further disruption of the BBB and BSCB
Dogs, the first domesticated animal, have been used in hunting, in security and in warfare, as have horses, pigeons and birds of prey; while other terrestrial and aquatic animals are hunted for sports, trophies or profits. Non-human animals are also an important element of human culture, having appeared in cave arts and totems since the earliest times, and are frequently featured in mythology, religion, arts, literature, heraldry, politics, and sports.
305200: type 5 130080: type 8 – unspecified gene, locus 12p13 225310: type 10 – unspecified gene, locus 2q34 608763: Beasley–Cohen type 130070: progeroid form – B4GALT7 130090: type unspecified 601776: D4ST1-deficient Ehlers–Danlos syndrome (adducted thumb-clubfoot syndrome) CHST14
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.
Cold, dry, and dark conditions are standard, typically at or below minus twenty degrees Celsius for long-term holding. Vials are usually warmed to room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is generally avoided.
This depends on pH, buffer, and concentration, with acidic conditions often reported as more favorable. Hydrolysis accelerates at room temperature, so solutions are commonly prepared fresh or stored frozen in single-use aliquots. No single shelf life applies across formulations.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.